Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2018 / Articles / Sep / Science Versus Sensationalism
Manufacture Advanced Medicine

Science Versus Sensationalism

Don’t give journalists an excuse to fuel the hype machine

By James Strachan 09/12/2018 1 min read

Share

I was recently invited to speak at the International Society Cell and Gene Therapy’s (ISCT’s) conference in Florence, Italy, on the communication of cellular therapies. The title of my presentation? “The Journalist’s Dilemma: Science Versus Sensationalism.” It’s clear that cell and gene therapies are incredibly exciting, with “the potential to transform medicine,” as FDA Commissioner Scott Gottlieb put it – so we journalists want to talk about them. But we also don’t want to sensationalize the research. I’ve heard stories of clinics being bombarded with calls from patients wanting to know if they could benefit from a CAR-T cell therapy, despite the fact that only around 300 patients are eligible for treatment. At the same time, we’ve got the growth of unproven cell therapy clinics, tapping into the hope (or hype)generated by media coverage.

There are often three steps to the science communication process: the journal article, the press release, and the news article – each with incentives to boost the impact of the research and play-down the caveats. Of course, the ultimate responsibility for the claims made in a news story lie with the journalist. But it turns out that a major source of hype in science news originates at the second stage: the university press releases. One study looked at hundreds of papers, press releases, and news articles and found that 33 percent of primary claims in press releases were more strongly deterministic than those present in the journal article (1). Thankfully, I’m able to check claims and often speak with authors directly – but others are less picky. And when an increasingly busy reporter is confronted with an enticing press release and, perhaps, a less-than-readable journal article (aflush with technical terms and unnecessarily complex language), it’s easy to understand where the problem arises. If we want effective science communication, we need researchers to take more responsibility for how institutions report their research; the whole “story” should be comprehensible to a busy news reporter.

It would appear that there are two types of sensationalizing journalists out there: the unscrupulous/incompetent and the lazy/busy. There isn’t a great deal that scientists can do about the former, but they can certainly have an impact on the latter. Please share science responsibly!

James Strachan Deputy Editor

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. P Sumner et al., “The association between exaggeration in health related science news and academic press releases: retrospective observational study,” BMJ 349 (2014).

About the Author(s)

James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at. From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.

More Articles by James Strachan

False

Advertisement

Recommended

False

Related Content

Don’t Forget CDx Developers
Advanced Medicine
Don’t Forget CDx Developers

November 7, 2014

0 min read

Many drug developers are going ‘full steam ahead’ with personalized medicine strategies. They would be wise to consider a more equitable business model for an essential partner in the process: the developer of the companion diagnostic.

The Next Decade of Cell and Gene Therapies
Advanced Medicine Bioprocessing - Upstream & Downstream Trends & Forecasts Digital Technologies
The Next Decade of Cell and Gene Therapies

May 7, 2025

5 min read

Off-the-shelf allogeneic CAR-Ts, increased manufacturing productivity led by digital systems, and more; we ask experts about the future of advanced medicine.

Peter Marks Resigns from FDA
Standards & Regulation Profession Vaccines Advanced Medicine
Peter Marks Resigns from FDA

April 1, 2025

3 min read

Resignation letter states: “truth and transparency” around vaccines are not desired by Health Secretary RJK Jr. “Rather he wishes subservient confirmation of his misinformation and lies.”

The Trump Effect on Cell and Gene: Science versus Shockwaves
Business Practice Standards & Regulation Trends & Forecasts Advanced Medicine
The Trump Effect on Cell and Gene: Science versus Shockwaves

April 1, 2025

9 min read

Audrey Greenberg on FDA staffing cuts, Peter Marks’ resignation, CDMO pressure, IP migration, AI acceleration, and what CGT needs now to stay on track.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.